- Home
- CSR vs CDNA Comparison
CSR vs CDNA Comparison
Compare CSR & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSR
- CDNA
- Stock Information
- Founded
- CSR 1970
- CDNA 1998
- Country
- CSR United States
- CDNA United States
- Employees
- CSR N/A
- CDNA N/A
- Industry
- CSR Real Estate Investment Trusts
- CDNA Medical Specialities
- Sector
- CSR Real Estate
- CDNA Health Care
- Exchange
- CSR Nasdaq
- CDNA Nasdaq
- Market Cap
- CSR 1.0B
- CDNA 1.0B
- IPO Year
- CSR N/A
- CDNA 2014
- Fundamental
- Price
- CSR $61.39
- CDNA $15.36
- Analyst Decision
- CSR Buy
- CDNA Buy
- Analyst Count
- CSR 8
- CDNA 7
- Target Price
- CSR $71.75
- CDNA $30.33
- AVG Volume (30 Days)
- CSR 102.4K
- CDNA 1.1M
- Earning Date
- CSR 05-01-2025
- CDNA 04-30-2025
- Dividend Yield
- CSR 5.07%
- CDNA N/A
- EPS Growth
- CSR N/A
- CDNA N/A
- EPS
- CSR N/A
- CDNA 1.07
- Revenue
- CSR $263,570,000.00
- CDNA $346,421,000.00
- Revenue This Year
- CSR $4.47
- CDNA $13.28
- Revenue Next Year
- CSR $3.67
- CDNA $15.13
- P/E Ratio
- CSR N/A
- CDNA $14.36
- Revenue Growth
- CSR 2.19
- CDNA 25.92
- 52 Week Low
- CSR $54.13
- CDNA $7.42
- 52 Week High
- CSR $76.16
- CDNA $34.84
- Technical
- Relative Strength Index (RSI)
- CSR 55.29
- CDNA 38.73
- Support Level
- CSR $59.51
- CDNA $14.09
- Resistance Level
- CSR $61.62
- CDNA $18.71
- Average True Range (ATR)
- CSR 1.86
- CDNA 1.03
- MACD
- CSR 0.32
- CDNA -0.18
- Stochastic Oscillator
- CSR 87.69
- CDNA 23.48
About CSR D/B/A Centerspace
Centerspace is a real estate investment trust (REIT) that focuses on the ownership, management, acquisitions, redevelopment, and development of apartment communities. The company operates through a single reportable segment which includes the ownership, management, development, redevelopment, and acquisition of apartment communities and conduct their corporate operations from offices in Minot, North Dakota and Minneapolis, Minnesota.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.